Gender differences in cardiac repolarization following intravenous sotalol administration

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 1, 2012, Pages 86-92

  Somberg, John C ^a   Preston, Richard A ^b   Ranade, Vasant ^c   Cvetanovic, Ivana ^a   Molnar, Janos ^c  

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Academic Pharmaceutical Inc   (United States)

Author keywords

gender differences; intravenous administration; QT prolongation; sotalol; torsade de pointes

Indexed keywords

SOTALOL;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; BODY SURFACE; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; ELECTROCARDIOGRAPHY MONITORING; FRAMINGHAM RISK SCORE; HEART REPOLARIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QT PROLONGATION; SEX DIFFERENCE; TORSADE DES POINTES; UNIVARIATE ANALYSIS;

ADULT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; SEX CHARACTERISTICS; SOTALOL; THERAPEUTIC EQUIVALENCY; TORSADES DE POINTES; YOUNG ADULT;

EID: 84856956749     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411406505     Document Type: Article

References (33)

1. Viskin S.. Long QT syndromes and torsade de pointes. Lancet. 1999 ; 354 (9190). 1625-1633 (Pubitemid 29515963)
2. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG.. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005 ; 26 (6). 590-597 (Pubitemid 40461101)
3. Shah RR.. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf. 2004 ; 27 (3). 145-172 (Pubitemid 38315325)
4. Yap YG, Camm AJ.. Drug induced QT prolongation and torsades de pointes. Heart. 2003 ; 89 (11). 1363-1372 (Pubitemid 37311108)
5. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH.. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993 ; 270 (21). 2590-2597 (Pubitemid 23346699)
6. Ebert SN, Liu XK, Woosley RL.. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998 ; 7 (5). 547-557
7. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ.. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996 ; 94 (10). 2535-2541
8. Tobin MD, Kähönen M, Braund P, et al. Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations. Int J Epidemiol. 2008 ; 37 (5). 1132-1141
9. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol. 1992 ; 8 (7). 690-695
10. Somberg JC, Preston RA, Ranade V, Molnar J.. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 ; 17 (4). 365-372
11. Somberg JC, Preston RA, Ranade V, Molnar J.. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology. 2010 ; 116 (3). 219-225
12. Fridericia LS.. Die systolendmrer im elektrokardiogramm bei normalen menchen und bei herzkranken. Acta Med Scand. 1920 ; 3: 469-486
13. Puddu PE, Jouve R, Mariotti S, et al. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: emphasis on the cubic root Fridericia's equation. J Electrocardiol. 1988 ; 21 (3). 219-229
14. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D.. An improved method for adjusting the QT interval for heart rate (the Framingham heart study). Am J Cardiol. 1992 ; 70 (7). 797-801
15. BetapaceBetapaceAF[package insert]. Physicians' Desk Reference. 57th Edition. Montvale, NJ: Thomson PDR; 2003:931-940. http://dailymed.nlm.nih.gov/ dailymed/drugInfo.cfm?id=13510Accessed January 2011.
16. Sotalol hydrochloride injection for intravenous use. Prescribing Informationhttp://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 022306s000lbl.pdfAccessed January 2011.
17. Anderson JL, Prystowsky EN.. Sotalol: an important new antiarrhythmic. Am Heart J. 1999 ; 137 (3). 388-409 (Pubitemid 29124104)
18. Singh BN.. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol. Am J Cardiol. 1990 ; 65 (2). 3A - 11A (Pubitemid 20019018)
19. Singh BN.. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents. Am J Cardiol. 1993 ; 72 (4). 8A - 18A (Pubitemid 23238407)
20. Singh BN, Vaughan Williams EM.. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol. 1970 ; 39 (4). 675-687
21. Singh BN, Antonaccio MJ Cardiovascular Pharmacology and Therapeutics. Singh BN, ed. New York, NY: Churchill Livingstone ; 1994: 727-745.
22. Kaumann AJ, Olson CB.. Temporal relation between long-lasting aftercontractions and action potentials in cat papillary muscles. Science. 1968 ; 161 (838). 293-295
23. Kurokawa J, Suzuki T, Furukawa T.. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: acute effects of female hormones on cardiac ion channels and cardiac repolarization. J Pharmacol Sci. 2009 ; 109 (3). 334-340
24. Yang PC, Clancy CE.. Effects of sex hormones on cardiac repolarization. J Cardiovasc Pharmacol. 2010 ; 56 (2). 123-129
25. Nakamura H, Kurokawa J, Bai CX, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study. Circulation. 2007 ; 116 (25). 2913-2922 (Pubitemid 350291198)
26. Kurokawa J, Tamagawa M, Harada N, et al. Acute effects of oestrogen on the guinea pig and human IKr channels and drug-inducedprolongation of cardiac repolarization. J Physiol. 2008 ; 586 (pt 12). 2961-2973 (Pubitemid 351837288)
27. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T.. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005 ; 112 (12). 1701-1710 (Pubitemid 41368145)
28. Furukawa T, Kurokawa J.. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias. Pharmacol Ther. 2007 ; 115 (1). 106-115 (Pubitemid 46990555)
29. Asada K, Kurokawa J, Furukawa T.. Redox- and calmodulin-dependent S-nitrosylation of the KCNQ1 channel. J Biol Chem. 2009 ; 284 (9). 6014-6020
30. Pham TV, Sosunov EA, Anyukhovsky EP, Danilo P, Rosen MR.. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation. 2002 ; 106 (16). 2132-2136 (Pubitemid 35192821)
31. Pham TV, Sosunov EA, Gainullin RZ, Danilo P, Rosen MR.. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation. 2001 ; 103 (17). 2207-2212 (Pubitemid 32458331)
32. Liu XK, Katchman A, Whitfield BH, et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res. 2003 ; 57 (1). 28-36 (Pubitemid 36009433)
33. Hara M, Danilo P, Rosen MR.. Effects of gonadal steroids on ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther. 1998 ; 285 (3). 1068-1072 (Pubitemid 28277905)